Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences Corp (NYSE:EW), executed a series of transactions involving the company's common stock on October 15, 2024.
Bobo sold 5,000 shares at a weighted average price of $69.51, totaling approximately $347,533. This transaction was part of a pre-arranged trading plan under Rule 10b5-1, adopted on December 14, 2023.
In a related move, Bobo exercised options to acquire 5,000 shares at a price of $45.28 per share, amounting to $226,383. Following these transactions, Bobo holds 46,935.72 shares directly, with additional shares held indirectly through a 401(k) and a trust.
These transactions reflect changes in Bobo's beneficial ownership of Edwards Lifesciences stock.
In other recent news, Edwards Lifesciences reported a $95 million revenue beat, achieving total sales of $1.63 billion. Following the sale of its Critical Care business to Becton Dickinson (NYSE:BDX), several firms, including Canaccord Genuity, Truist Securities, and Barclays (LON:BARC), revised their price targets for Edwards Lifesciences. Baird's analyst David Rescott increased the price target to $73.00, maintaining a Neutral rating on the company's stock, while Morgan Stanley (NYSE:MS) set a price target of $70.00 highlighting the company's strong financial position.
However, Jefferies downgraded the company's stock rating from 'Buy' to 'Hold', citing concerns about the growth prospects for its Transcatheter Aortic Valve Replacement (TAVR) products. Conversely, TD Cowen reaffirmed its Hold rating, influenced by anticipated favorable outcomes from the company's Early TAVR trial.
Piper Sandler maintained a neutral position on shares of Edwards Lifesciences, emphasizing the upcoming presentation of the EARLY-TAVR study results. Meanwhile, Canaccord Genuity revised its price target for Edwards Lifesciences from $77.00 to $66.00, while maintaining a Hold rating, and adjusted its earnings per share estimates for 2025 and 2026 by $0.48 each year.
These are recent developments in Edwards Lifesciences' financial landscape, reflecting various analyst perspectives and financial adjustments following the company's recent business sale and earnings report.
InvestingPro Insights
To provide context for Donald E. Bobo Jr.'s recent stock transactions, let's examine some key financial metrics for Edwards Lifesciences Corp (NYSE:EW). According to InvestingPro data, the company currently has a market capitalization of $41.55 billion and trades at a P/E ratio of 28.2, which is relatively high compared to its near-term earnings growth potential.
Despite the recent insider selling, Edwards Lifesciences has shown strong financial performance. The company's revenue for the last twelve months as of Q2 2023 stood at $6.2 billion, with an impressive revenue growth of 19.3% over the same period. This growth is complemented by a robust gross profit margin of 76.38%, indicating efficient operations and pricing power in its market segments.
InvestingPro Tips highlight that management has been aggressively buying back shares, which could be seen as a vote of confidence in the company's future prospects. This action may also help support the stock price, potentially offsetting the impact of insider sales like Bobo's.
It's worth noting that Edwards Lifesciences operates with a moderate level of debt and its liquid assets exceed short-term obligations, suggesting a solid financial position. This financial stability could provide reassurance to investors in light of the recent insider transaction.
For readers interested in a more comprehensive analysis, InvestingPro offers 11 additional tips for Edwards Lifesciences, providing a deeper insight into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.